A new trade deal eliminates tariffs on pharmaceuticals between the UK and the US, strengthening transatlantic trade. This creates a powerful tailwind for pharmaceutical companies in both countries, potentially boosting exports, innovation, and profitability.
Veröffentlicht am Dezember 2
This is the first major pharmaceutical trade deal between the UK and US, creating unprecedented opportunities for companies on both sides of the Atlantic to boost profitability and market access.
Tariff elimination means direct cost reductions for pharmaceutical exports, potentially improving profit margins for established players like GSK and AstraZeneca whilst opening new revenue streams.
Enhanced collaboration between UK and US biotech firms could accelerate drug development and research partnerships, particularly benefiting smaller clinical-stage companies in both markets.
The elimination of pharmaceutical tariffs between the UK and US creates a powerful financial tailwind for drugmakers in both countries. This landmark agreement reduces export costs, improves profit margins, and strengthens economic ties between two major economies. We've identified companies positioned to benefit from increased market access and streamlined trade flows.
This group includes major UK pharmaceutical exporters like GSK and AstraZeneca alongside leading US biotech firms. These companies stand to gain from reduced trade barriers, lower distribution costs, and enhanced collaboration opportunities. The deal addresses long-standing trade imbalances whilst boosting innovation potential on both sides of the Atlantic.
Each company was handpicked by professional analysts based on their strategic positioning to capitalise on this trade breakthrough. From established giants with significant cross-border operations to innovative biotech firms developing specialised treatments, these stocks represent the best opportunities to benefit from tariff-free pharmaceutical trade between the UK and US.
This basket's total market capitalisation is $813.93B. It is heavily anchored by several very large-cap stocks, which likely gives it a relatively stable, large-cap profile and closer tracking of broad-market moves.
GSK: $97.00B
AZN: $283.99B
BMY: $100.12B
Erfahren Sie alles über diesen Aktienkorb. Lesen Sie unseren ausführlichen Artikel zu seinen Risiken und seinem Potenzial.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+8
Here are a few of the assets in this group. Create an account to unlock the full list.
GlaxoSmithKline
GSK
Aktueller Kurs
$48.13
As a major UK-based global biopharma company with significant US operations, GSK is perfectly positioned to benefit from eliminated tariffs and streng...
As a major UK-based global biopharma company with significant US operations, GSK is perfectly positioned to benefit from eliminated tariffs and strengthened transatlantic trade.
ASTRAZENECA PLC
AZN
Aktueller Kurs
$160.16
This UK-based global biopharmaceutical giant with a large US presence will likely see improved profitability and streamlined distribution from a tarif...
This UK-based global biopharmaceutical giant with a large US presence will likely see improved profitability and streamlined distribution from a tariff-free trade agreement.
Bristol Myers Squibb
BMY
Aktueller Kurs
$63.62
This major US-based biopharmaceutical company is set to gain from easier access to the UK market and potentially lower costs for transatlantic researc...
This major US-based biopharmaceutical company is set to gain from easier access to the UK market and potentially lower costs for transatlantic research and development.
Join Nemo FREE today and unlock every stock
Es dauert nur 60 Sekunden.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitiv Ltd.
Wenn Sie in diese Werte investieren:
In 12 Monaten könnte der Wert betragen:
+48.73%
Analysten erwarten im Durchschnitt, dass die Werte dieser Gruppe im nächsten Jahr um 48.73 % zulegen.
14 von 14 Werten dieser Gruppe werden von professionellen Analysten mit „Kaufen“ bewertet.
